Cargando…

Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide

Fatigue is a common non-motor symptom in Parkinson’s disease (PD). Among other pathophysiological mechanisms, neuroinflammation, a pathological PD hallmark associated with changes in glutamatergic transmission in basal ganglia, has been proposed as a crucial factor closely related to fatigue. To tes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pauletti, Caterina, Locuratolo, Nicoletta, Mannarelli, Daniela, Maffucci, Andrea, Petritis, Alessia, Menini, Elisa, Fattapposta, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2023
Materias:	Neurology and Preclinical Neurological Studies - Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293124/ https://www.ncbi.nlm.nih.gov/pubmed/37210459 http://dx.doi.org/10.1007/s00702-023-02654-1

Ejemplares similares

Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study
por: De Masi, Claudia, et al.
Publicado: (2022)

Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A post hoc analysis of the SETTLE study
por: Bhidayasiri, Roongroj, et al.
Publicado: (2023)

The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review
por: Sharaf, Joudi, et al.
Publicado: (2022)

Effects of Cerebellar tDCS on Inhibitory Control: Evidence from a Go/NoGo Task
por: Mannarelli, Daniela, et al.
Publicado: (2020)

Age-Related Psychophysiological Vulnerability to Phenylalanine in Phenylketonuria
por: Leuzzi, Vincenzo, et al.
Publicado: (2014)

A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
por: Kulisevsky, Jaime, et al.
Publicado: (2022)

Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Efficacy of Safinamide and Gender Differences During Routine Clinical Practice
por: Pellecchia, Maria T., et al.
Publicado: (2021)

The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease: Post-hoc Analysis of a Japanese Phase 2/3 Study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

The Seasonal Fluctuation of Fatigue in Multiple Sclerosis
por: Grothe, Matthias, et al.
Publicado: (2022)

Gender differences in non-motor fluctuations in Parkinson’s disease
por: Donzuso, Giulia, et al.
Publicado: (2023)

The Role of the Right Dorsolateral Prefrontal Cortex in Phasic Alertness: Evidence from a Contingent Negative Variation and Repetitive Transcranial Magnetic Stimulation Study
por: Mannarelli, Daniela, et al.
Publicado: (2015)

Fluctuations in Parkinson’s disease and personalized medicine: bridging the gap with the neuropsychiatric fluctuation scale
por: Schmitt, Emmanuelle, et al.
Publicado: (2023)

Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2021)

Quality of life: Seasonal fluctuation in Parkinson's disease
por: Wu, Lei, et al.
Publicado: (2023)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson's Disease
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2021)

Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations
por: Fernandes, Mariana, et al.
Publicado: (2021)

Impact of non-motor fluctuations on QOL in patients with Parkinson’s disease
por: Kakimoto, Asako, et al.
Publicado: (2023)

Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease
por: Prell, Tino, et al.
Publicado: (2019)

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

Executive functioning and serum lipid fractions in Parkinson’s disease—a possible sex-effect: the PACOS study
por: Luca, Antonina, et al.
Publicado: (2022)

Predicting the fatigue in Parkinson's disease using inertial sensor gait data and clinical characteristics
por: Wang, Hui, et al.
Publicado: (2023)

Deconstructing Apathy in Parkinson's Disease: Challenges in Isolating Core Components of Apathy From Depression, Anxiety, and Fatigue
por: Ineichen, Christian, et al.
Publicado: (2021)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

Poor sleep quality is associated with fatigue and depression in early Parkinson's disease: A longitudinal study in the PALS cohort
por: Koh, Matthew Rui En, et al.
Publicado: (2022)

Cannabinoid Effect and Safety in Spasticity Following Stroke: A Double-Blind Randomized Placebo-Controlled Study
por: Marinelli, Lucio, et al.
Publicado: (2022)

Looking deeper: does a connection exist between fatigue and attentional deficits in Parkinson's disease? A conceptual framework
por: Ortelli, Paola, et al.
Publicado: (2023)

Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Role of Functional Neuroimaging with 123I-MIBG and 123I-FP-CIT in De Novo Parkinson’s Disease: A Multicenter Study
por: De Feo, Maria Silvia, et al.
Publicado: (2023)

The heterogeneity of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2023)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Olfaction in patients with Parkinson’s disease: a new threshold test analysis through turning points trajectories
por: Cecchini, Maria Paola, et al.
Publicado: (2021)

Glucocerebrosidase mutations and Parkinson disease
por: Vieira, Sophia R. L., et al.
Publicado: (2022)

Life style and Parkinson’s disease
por: Reichmann, Heinz, et al.
Publicado: (2022)

Molecular Hydrogen as a Medical Gas for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Possible Efficacy Based on a Literature Review
por: Hirano, Shin-ichi, et al.
Publicado: (2022)

An attempt to dissect a peripheral marker based on cell pathology in Parkinson's disease
por: Biagioni, Francesca, et al.
Publicado: (2021)

Treatment of Parkinson’s disease in the advanced stage
por: Ossig, C., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6gqr5enufb7ugui47irevclv4j